News Spark reassures on safety of haemophilia gene therapy Study of nine patients produce encouraging results
News CAR-Ts to take centre stage at ASH haematology congress Haematology is one of the most exciting areas in drug development today, with waves of new treatments emerging for hard-to-treat diseases.
News CRISPR Therapeutics plans Nasdaq launch CRISPR Therapeutics, the Swiss genome-editing company, has filed for a $90 million initial public offering.
News Biogen’s haemophilia spin-out Bioverativ to launch early 201... Coming antibody drugs and gene therapy could transform treatment
News New haemophilia drug Elocta approved in Europe Elocta, a new drug co-marketed by Sobi and Biogen, has been approved in the European Union.
News MSD stops trials of BTK inhibitor for blood cancers MSD has stopped development of BTK inhibitor nemtabrutinib, acquired via its $2.7bn takeover of ArQule, after trial results pointed to a safety issue.
Sales & Marketing Sponsored Securing your ROI: Turning post-acquisition integration into... Join Forinnovia and Little Cube Consulting for a webinar on securing post-acquisition ROI.